Best Peptides for Weight Loss in 2026: Evidence-Based Rankings
Evidence-ranked review of peptides for weight management in 2026. Only FDA-approved and late-stage clinical compounds, ranked by strength of evidence — not marketing claims.
Finding the “best peptide for weight loss” depends entirely on what you mean by “best.” Marketing claims and anecdotal reports favor compounds with dramatic-sounding names and limited oversight. Evidence-based rankings look different.
This article ranks weight-loss peptide compounds by evidence quality — not by peak weight loss percentage, not by social media popularity, and not by the strength of manufacturer claims. A compound with five large randomized controlled trials and FDA approval ranks higher than one with 24% weight loss in a single phase 2 study with no long-term safety data.
How We Rank
Every entry in this guide is ranked using the following hierarchy:
| Evidence Tier | Criteria | Example |
|---|---|---|
| Tier 1 | FDA-approved, multiple RCTs, cardiovascular outcomes data | Semaglutide |
| Tier 2 | FDA-approved, multiple RCTs, no CV outcomes yet | Tirzepatide, Liraglutide |
| Tier 3 | FDA approval pending (NDA filed) or Phase 3 complete | CagriSema |
| Tier 4 | Phase 3 in progress, Phase 2 published in major journals | Retatrutide |
| Tier 5 | Phase 1-2 only, limited published data | Other investigational |
| Not ranked | No human RCT data for weight loss | AOD-9604, MK-677 for obesity |
Approval by the FDA requires demonstrated efficacy in at least two Phase 3 trials and a safety review. That standard is why approved agents rank above investigational ones regardless of how promising the Phase 2 numbers look.
One rule: No dosing information or sourcing guidance in this guide. Rankings are for informational purposes only and do not constitute medical advice.
The Rankings
1. Semaglutide — Strongest Evidence Base
Mechanism: GLP-1 receptor agonist Products: Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D) FDA status: Approved for obesity (2021) and type 2 diabetes (2017)
Semaglutide has more published human trial data for weight management than any other peptide in this class. The STEP clinical program enrolled over 15,000 participants across multiple indications.
Key evidence:
- STEP-1 trial: 14.9% mean weight loss at 68 weeks in adults with obesity (N=1,961) [pmid-33567185]
- SELECT trial: 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease [pmid-37952131]. This cardiovascular outcomes data is a major differentiator — no other obesity drug in this class has equivalent published CVOT data.
- Approved in 14 indications across diabetes, obesity, cardiovascular risk, and kidney disease.
Why it ranks first: Largest evidence base, longest safety follow-up among GLP-1 agonists, proven cardiovascular benefit. Its weight loss numbers (typically 15-17% in trials) are lower than newer agents, but its evidence breadth is unmatched.
2. Tirzepatide — Highest Efficacy Among Approved Agents
Mechanism: Dual GIP/GLP-1 receptor agonist Products: Mounjaro (T2D), Zepbound (obesity) FDA status: Approved for obesity (2023) and type 2 diabetes (2022)
Tirzepatide added GIP receptor activation to GLP-1 agonism, producing greater weight loss than semaglutide in clinical trials. It is the most effective FDA-approved pharmacological weight loss treatment available as of 2026.
Key evidence:
- SURMOUNT-1 trial: 22.5% mean weight loss at 72 weeks with the 15mg dose in adults with obesity (N=2,539) [pmid-35658024]. Over 60% of participants achieved 20% or greater weight loss.
- SURMOUNT-5 head-to-head: Tirzepatide 15mg outperformed semaglutide 2.4mg in a direct randomized comparison (20.2% vs 13.7% weight loss at 72 weeks) [pmid-39107523]. This is the only head-to-head RCT between two approved agents in this class.
- Approved for chronic weight management in multiple countries with extensive global trial data.
Why it ranks second: Highest efficacy of any approved agent with robust RCT evidence. The main gap relative to semaglutide is the absence of cardiovascular outcomes data — the SURMOUNT-MMO cardiovascular trial is underway but not yet completed.
3. Liraglutide — Established, Longest Track Record
Mechanism: GLP-1 receptor agonist Products: Saxenda (obesity), Victoza (T2D) FDA status: Approved for obesity (Saxenda, 2014), type 2 diabetes (Victoza, 2010)
Liraglutide is the original long-acting GLP-1 agonist for weight management, FDA-approved for obesity since 2014 — longer than semaglutide or tirzepatide. It has the most years of real-world safety data in the GLP-1 class.
Key evidence:
- SCALE Obesity trial: 8.0% mean weight loss versus 2.6% placebo at 56 weeks in adults with overweight or obesity (N=3,731) [pmid-25673378]
- LEADER trial (T2D): Demonstrated cardiovascular benefit in type 2 diabetes patients, providing early cardiovascular outcomes data for the GLP-1 class
- Proven safety profile over a decade of clinical use
Why it ranks third: Lower weight loss efficacy (~8% vs 15-22% for newer agents) limits clinical utility in 2026 when more effective options exist. However, its decade of real-world safety data and established cardiovascular benefit in T2D are genuine advantages. It is still widely used, particularly in patients who have been stable on it, and generic liraglutide (generic Saxenda) received FDA approval in 2025, improving affordability.
4. CagriSema — NDA Filed, Phase 3 Complete
Mechanism: GLP-1 agonist (semaglutide) + amylin analog (cagrilintide) Status: NDA filed with FDA (Novo Nordisk), not yet approved Developer: Novo Nordisk
CagriSema combines semaglutide with cagrilintide, a long-acting amylin analog. Amylin is a hormone co-secreted with insulin that complements GLP-1’s action on appetite and gastric emptying. The combination targets weight loss through two distinct but complementary mechanisms.
Key evidence:
- REDEFINE-1 trial: 22.7% mean weight loss at 68 weeks, compared to 15.6% with semaglutide alone and 8.1% with cagrilintide alone
- NDA submitted to FDA, which would make it the first GLP-1/amylin combination product if approved
- Phase 3 data supports additive effect beyond semaglutide monotherapy
Why it ranks fourth: Phase 3 data is compelling and an NDA has been filed, but FDA approval has not yet been granted. Once approved, CagriSema could rank alongside or above tirzepatide depending on final labeling and outcomes trial data.
5. Retatrutide — Most Promising Phase 3 Investigational Agent
Mechanism: Triple GIP/GLP-1/glucagon receptor agonist Status: Phase 3 (TRIUMPH program, Eli Lilly), not FDA-approved Developer: Eli Lilly
Retatrutide adds glucagon receptor activation to the dual-agonist approach of tirzepatide. The glucagon receptor drives hepatic fat oxidation and thermogenesis in brown adipose tissue — effects that may explain its greater weight loss compared to dual-agonist approaches.
Key evidence:
- Phase 2 NEJM trial: 24.2% weight loss at 48 weeks (12mg dose), published in the New England Journal of Medicine [pmid-37366315]. Weight loss was still ongoing at 48 weeks with no observed plateau.
- TRIUMPH-4 Phase 3: 28.7% mean weight loss at 68 weeks — the highest body weight reduction reported in any Phase 3 pharmacological trial. However, this is a single Phase 3 readout in a specific population (obesity with knee osteoarthritis), not the full Phase 3 picture.
- Triple agonist mechanism well-characterized through receptor binding and PK/PD studies.
Why it ranks fifth despite highest weight loss numbers: Phase 3 is incomplete. Cardiovascular outcomes trial is underway but not published. One Phase 3 readout does not establish the full safety and efficacy profile required for regulatory approval. An FDA-approved drug with published cardiovascular outcomes data provides a higher certainty standard than a Phase 3 compound, regardless of the weight loss number.
What About Other Peptides?
Several peptides are frequently mentioned in the context of weight loss but do not qualify for this ranking. Here is an honest assessment.
AOD-9604 — A fragment of human growth hormone (GH), positions 177-191. This fragment was studied for obesity but Phase 2 trials (METAOD) did not demonstrate significant weight loss in humans. AOD-9604 did not receive FDA approval for obesity. Preclinical lipolytic data exists, but human evidence for meaningful weight loss is insufficient. It does not belong in the same category as GLP-1 receptor agonists.
MK-677 (Ibutamoren) — A growth hormone secretagogue that raises GH and IGF-1. It is not a peptide (it is a small molecule), and while elevated GH can influence body composition, MK-677 is not studied or approved for weight management. GH elevation can worsen insulin resistance, which counteracts weight management goals. MK-677 does not have human RCT data for weight loss and should not be compared to GLP-1 agents for this purpose.
Sermorelin, CJC-1295, Ipamorelin — Growth hormone secretagogues (GHRH or GHRP class). These increase GH release and may influence body composition, but they are not studied in weight loss RCTs and have no FDA indication for obesity. GH effects on body composition are secondary to direct fat loss mechanisms. Not comparable to GLP-1 agents for weight loss efficacy.
BPC-157 — A synthetic gastric pentadecapeptide. No weight loss mechanism, no obesity-related clinical trials. Not relevant to this comparison.
The pattern across these compounds is the same: activity in preclinical or small pilot studies, absence of large randomized controlled trials for weight loss, no FDA approval for obesity management.
Key Takeaways
Evidence quality outranks efficacy numbers. A 28.7% weight loss in Phase 3 from a single trial is impressive but does not exceed the certainty of five Phase 3 trials, FDA approval, and a cardiovascular outcomes study.
FDA approval means something. The regulatory review process requires demonstration of safety and efficacy in controlled conditions, manufacturing quality, and post-marketing surveillance. This is not a trivial bar.
The ranking will shift. CagriSema’s NDA is pending. Retatrutide’s full Phase 3 program will complete. Cardiovascular outcomes data for tirzepatide is expected. The evidence landscape in 2026 is active, not static.
Consult a physician. All agents in the Tier 1-4 rankings are prescription medications or investigational drugs — none are available over the counter or through research chemical vendors. Anyone claiming to sell these compounds outside a pharmacy or clinical trial is not selling what they claim.
This article is for educational purposes only and does not constitute medical advice. Weight management medications require medical evaluation and prescription. Investigational compounds are available only through clinical trials. Consult a qualified healthcare provider.
Sources & Citations
- 2
- 6journalLiraglutide 3.0 mg for Weight Management — SCALE Obesity trial (Pi-Sunyer et al., 2015)
pmid-25673378
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.